SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below key support levels are dominating discussion, with traders pointing to leveraged-long liquidations and broader risk-off pressure across crypto and tech as possible contributors. The community is split between warnings of further downside and calls to buy an oversold dip or watch for support.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas reiterated that topline results from its Phase 3 REGAL trial of GPS in AML are expected in November after the trial reached its required event milestone, drawing attention to the pending binary readout. Traders are broadly excited about the prospect of positive data and a short squeeze, while speculation about a leak or buyout remains unconfirmed and skeptics stress that results have not been released and the trial outcome is uncertain.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about work interruptions and concern that the prolonged disruption could damage trust or pressure the stock. Some traders speculated about a cyberattack, but the cause was not confirmed, and others questioned why shares held relatively steady.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline toward the $1 support level amid a broader crypto selloff is dominating discussion, with traders pointing to Bitcoin weakness, inflation and rate concerns, and liquidations. Bears warn of further downside and question Ripples ability to provide catalysts, while some holders view the drop as a buying opportunity and continue accumulating.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Weakness in Ethereum and broader crypto-linked stocks is weighing on BitMine, while traders also criticize its underperformance and question managements spending, transparency, and buybacks. Some see the stocks discount to its crypto holdings as a buying opportunity, but bearish posts argue falling ETH prices can overwhelm any support from repurchases.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure as Bitcoin and broader crypto markets sell off, with traders highlighting COINs repeated new lows and weak performance even when Bitcoin stabilizes. Bearish calls dominate, though some see the decline as oversold and are buying the dip.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Global Health Publishes Postal Ballot Voting Results and Scrutinizer’s Report

Global Health Limited ( ($IN:MEDANTA) ) has provided an announcement. Global Health Limited, the operator of Medanta hospitals, is a listed Indian ...

Medanta Ranked India’s Best Hospital by Newsweek

• Named No. 1 in the country in list of ‘World’s Best Hospitals 2026’ • Among top global healthcare institutions for the seventh year running Gurugram, Haryana, India – Business Wire India Medanta – The Medicity, Gurugram, operated by Global Health Limited, has been ranked the No. 1 hospital in India in Newsweek’s prestigious ‘World’s […]

Cardiac care at a new era: Medanta showcases future of advanced heart treatment

Guwahati, January 28 : Cardiovascular diseases (CVDs) are a major and growing public health concern in Assam and have emerged as one of the leading causes of death in adults above the age of 40 years. Further, studies have indicated that people living in urban areas, including hilly regions, are increasingly vulnerable to CVDs, often well before they turn 40. Gurgaon-based Medanta - The Medicity, named the Best Private Hospital in India by Newsweek for six years in a row, leads the way in clinical research and advanced treatment options for a wide range of cardiac diseases, including Coronary Artery Disease (CAD) and Valvular Heart Disease (VHD). In a continued effort to improve medical care in the Northeastern states, Medanta brought its specialized expertise to Guwahati, with Dr. Praveen Chandra, Chairman, Interventional Cardiology, Cardiac Care at Medanta. The Medicity emphasizes the urgent need for early detection and management of advanced cardiac conditions. He further underscored Medanta's commitment to making world-class healthcare accessible to patients across the country.

Brief Healthcare: Primer: HeXun Biosciences (6986 TT) - Nov 2025 and more

In this briefing: Primer: HeXun Biosciences (6986 TT) - Nov 2025 Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. Primer: HeXun Biosciences (6986 TT) - Nov 2025 HeXun Biosciences operates a unique and synergistic dual-strategy business model, leveraging stable cash flow from its Contract Development and Manufacturing Organization (CDMO) services to fund its in-house development of high-potential stem cell-based new drugs. The company is strategically positioned in the high-growth regenerative medicine and biologics markets, with a focus on mesenchymal stem cells (MSCs) for cardiovascular diseases, a leading cause of death globally. Recent financial performance demonstrates exceptional growth, with revenue increasing by 119.36% and net income by 339.62% in the most recent fiscal year, transitioning the company from a loss-making entity to a profitable one with strong margin expansion.

Brief Healthcare: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook and more

In this briefing: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 1. Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook For 3Q25, Classys reported in-line revenue of W83bn (+40% YoY) and below-consensus operating profit of W37.6bn (+30% YoY; OP margin of 45.3%). By category, aesthetic device revenue grew 30% YoY to W42.9bn, consumables revenue expanded 46% YoY to W37.3bn, and other revenue surged 310% YoY to W2.7bn. By region, domestic revenue climbed 57% YoY to W29.8bn, and overseas revenue increased 32% YoY to W53bn. Excluding Brazil, overseas revenue expanded 80% YoY. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Healthcare: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... and more

In this briefing: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 Canbas Co Ltd (4575 JP): Q1 FY 06/26 flash update 1. Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Revenue In Line; Profitability Impacted by New Units: KIMS reported revenue broadly in line with our estimates, while EBITDA and PAT came in below expectations due to the initial ramp-up of new hospitals and the resultant operating deleverage. Profitability was impacted by higher depreciation and interest costs associated with the new facilities introduced. Reported revenue stood at 961 Cr, with margins at 21.2%, impacted by the addition of new units. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

In this briefing: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY Robust Execution and Order Pipeline to Fuel H2FY26 Growth: Wabag delivered a 19% YoY growth in revenue for Q2FY26, broadly meeting our estimates. Revenue recognition is typically skewed towards the second half of the year, indicating strong H2. The management mentioned that margins may vary on a quarterly basis, while the medium-term margin outlook remains intact. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Equities Bottom-Up: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

Brief Equities Bottom-Up: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 and more

In this briefing: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Calix’s Next Frontier: Can MDUs & International Push Boost Its Market Performance? 1. KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Macro Environment Outlook: The overall macro environment has shown a marked improvement, with uncertainty levels reducing by over 50% compared to Q4FY25. Europe displayed strong traction during the quarter as clients began transitioning their supply chains from local to more globally integrated ecosystems. Deal Wins/Pipeline: The company announced a major multi-year, multi-domain deal from a leading European OEM. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI and more

In this briefing: Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch HPG [BUY +38.0%] - Local, Global Tailwinds Support Solid Outlook VCB [BUY +25.3%] - EPS Growth to Improve in 2026-27; Attractive Valuation 1. Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Strong Operating Metrics: EOP REIT’s revenue rose 13% YoY to Rs 1,124 Cr, supported by portfolio expansion, strong leasing, and rent escalations. Total office space expanded 7% YoY to 40.9 Mn sq. ft., with new additions at Embassy Tech Village and Embassy Manyata. Healthy pre-leasing levels (97–100%) and lower vacancies lifted occupancy by 300 bps YoY to 90%. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Uptick in Revenue and Profitability: Revenue, EBITDA, and Adjusted PAT increased by 9.1%, 25.7%, and 29.2% YoY, respectively, driven by strong demand in API, especially in the export market, leading to overall volume growth of 9% and negative variance of ~2%.

Global Health Ltd. engages in the provision of healthcare, pathology, and other medical services. It engages in the research and development activities related to drugs, surgery, medical devices and equipment. The company was founded on August 13, 2004 and is headquartered in Gurugram, India.

Global Health Ltd.

Medanta Breaks Out On High Volumes; SEBI RAs Eye ₹1,375–₹1,380 Upside

Equity

Neutral Sentiment

Global Health, the company behind the Medanta hospital chain, is drawing attention from technical analysts after a sharp surge and breakout on strong volumes.&nbsp;SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/sameerpande">Sameer Pande</a> observed signs of a positive reversal forming on the monthly chart, supported by a healthy relative strength index (RSI) reading around 65.&nbsp;<stembedurl>https://stocktwits.com/sameerpande/message/620283641</stembedurl>On the daily chart, he pointed to a breakout above the supertrend line, with RSI nearing 70.&nbsp;According to him, ₹1,300 is a key level to watch, and a clean move above it could open the path to ₹1,380. He suggested that traders consider buying above ₹1,300 or look for entries closer to the ₹1,230–₹1,200 demand zone, with a stop-loss set at ₹1,180 on a closing basis.Meanwhile, SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/VijayGuptaAdvisory">Vijay Kumar Gupta</a> noted that the stock has broken out of a long consolidation zone, with a notable rise in volume.&nbsp;<stembedurl>https://stocktwits.com/VijayGuptaAdvisory/message/620287099</stembedurl>He identified ₹1,229–₹1,230 as a zone that had acted as resistance, and is now likely to act as support.&nbsp;Gupta said that a hold above ₹1,230–₹1,220 would be a sign of strength, while deeper support lies at ₹1,150–₹1,160 and further down at ₹1,050–₹1,030. His strategy includes watching for a pullback near ₹1,230–₹1,220 for a potential bounce, or adding above ₹1,300 if the move is backed by strong volume.&nbsp;He said a breakout beyond ₹1,300 could take the stock toward ₹1,350–₹1,375.&nbsp;At the same time, he flagged ₹1,220 as a key level and said if the stock fails to hold it, traders should be cautious and monitor the lower support areas.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/MEDANTA.NSE">Global Health</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.The stock has risen 17.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global Health, the company behind the Medanta hospital chain, is drawing attention from technical analysts after a sharp surge and breakout on strong volumes. 

The analysts said that demand zones between ₹1,230–₹1,200 and ₹1,150–₹1,030 may offer entry opportunities on pullbacks.

Current Price	1,450.50
Prev Close	1,439.90
Open	1,445.00
Dividend Yield	0.05%
50-Day Moving Average	1,363.49
Beta	N/A
Avg. Volume	190,743.32
PE Ratio	62.54

52-Week High	1,544.00
52-Week Low	956.00
Market Capitalization	384.11B
EPS (Annual)	20.71
Price to Book	8.95
Revenue Per Employee	2.93M

Feed

News

Sentiment

Fundamentals

Info

MEDANTA.NSE Fundamentals